louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01756573: Dexamethasone and Block Duration in Upper Extremity
Official title: A Study of the Effect of Dexamethasone on Duration of Upper Extremity Blocks With Bupivacaine
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Duration of Pain Relief
Keywords: block duration
analgesia
Lead sponsor: University of Chicago
Sponsor class: OTHER
First posted: 2012-12-27
Enrollment: 5
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Effect of dexamethasone on prolonging upper extremity block is well known. But it not known if the effect comes from its local effect on the nerves or from its general analgesic effect. In this study we will compare the systemic effect to its local effect to find out if there is a difference or not.


Eligibility criteria: Inclusion Criteria:

* age 18-75, no contraindication to regional anesthesia,

Exclusion Criteria:

* opioid user, chronic pain conditions, peripheral neuropathy

Primary outcomes:
measure: Analgesia Duration
timeFrame: 72 hrs
Secondary outcomes:
Other outcomes:
Locations:
city: Chicago
country: United States
facility: University of Chicago Medical Center
state: Illinois
Study officials:
affiliation: University of Chicago
name: Tariq Malik, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02497027: Pharmacogenetic Testing in an Outpatient Population of Patients With Depression
Official title: Pharmacogenetic Testing in an Outpatient Population of Patients With Major Depressive Disorder or Depressive Disorder Not Otherwise Specified
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Depression
Keywords: pharmacogenetic, pharmacogenomic, depressive, mental health
Lead sponsor: Avera McKennan Hospital & University Health Center
Sponsor class: OTHER
First posted: 2015-07-14
Enrollment: 83
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: This is a randomized, control group design of pharmacogenetic implementation in a mental health population of subjects taking anti-depressants and/or anti-psychotics with a new or current primary or secondary diagnosis of Major Depressive Disorder (MDD) or Depressive Disorder Not Otherwise Specified (DDNOS).

Detailed description: This is a randomized, control group design of pharmacogenetic implementation in a mental health population of subjects taking anti-depressants and/or anti-psychotics with a new or current primary or secondary diagnosis of Major Depressive Disorder (MDD) or Depressive Disorder Not Otherwise Specified (DDNOS). Prospective data will be collected on all subjects until study completion at 24-25 weeks post enrollment. Claims data may be reviewed per pay, if such data are readily available in a timely manner.

Eligibility criteria: Inclusion Criteria:

* Current primary or secondary diagnosis of Major Depressive Disorder or Depressive Disorder Not Otherwise Specified
* Have moderate to severe depression as identified by PHQ-9 scoring of 10 or greater
* Taking or be newly prescribed an anti-depressant or anti-psychotic medication
* Able to provide informed consent
* Prescribing physician practices at the Avera Medical Group University Psychiatry Associates clinic in Sioux Falls, SD

Exclusion Criteria:

* Pregnant or breastfeeding
* Active and/or unstable diagnosis of substance abuse, excluding nicotine
* Primary diagnosis of dementia, bipolar disorder (any type), schizophrenia, schizoaffective disorder, or personality disorder

Primary outcomes:
measure: Depression score
timeFrame: 24 weeks
Secondary outcomes:
measure: Clinical utility questionnaire
timeFrame: 24 weeks
Other outcomes:
Locations:
city: Sioux Falls
country: United States
facility: Avera McKennan Hospital & University Health Center
state: South Dakota
Study officials:
affiliation: Avera McKennan Hospital & University Health Center
name: Matthew Stanley, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00345527: A Randomized Control Trial Examining Two Treatments for Problem Gambling
Official title: A Randomized Control Trial Examining Two Treatments for Problem Gambling
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Gambling, Pathological
Anger
Keywords: Problem gambling
Clinically significant anger
Lead sponsor: Centre for Addiction and Mental Health
Sponsor class: OTHER
First posted: 2006-06-28
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Despite evidence of high rates of concurrent substance use and anger problems among problem gamblers, until recently there have been no empirically evaluated treatments for these co-morbid problems. A recent study (Korman, Collins, McMain, \& Skinner, 2005) found that an emotion and behaviour regulation treatment (EBRT) was more effective than a gambling-only treatment-as-usual in engaging clients in treatment and in reducing gambling, anger, and substance use. This study is a replication of Korman et al's study and will compare an emotion and behaviour regulation treatment (EBRT) for problem gambling, anger and substance use to a manualized cognitive behavioural treatment (CBT) for problem gambling.

Detailed description: 80 participants will be randomly assigned to either an emotion and behaviour regulation treatment (EBRT) or to a cognitive behavioural treatment (CBT). Randomization will be stratified by the presence of substance dependence disorder. Both treatment conditions will consist of 12 one-hour weekly outpatient individual sessions. Participants will be assessed at baseline, end of treatment, and 3-months, 6-months and 12-months follow-up.

Eligibility criteria: Inclusion Criteria:

* Problem gambling (PGSI \> 7; c.f., Ferris \& Wynne, 2001)
* Clinically significant anger (STAXI-II anger expression/trait subscale score \>75th percentile and/or Anger Control subscale score \< 25th percentile; c.f., Spielberger, 1999)

Exclusion Criteria:

* Major thought disorders
* Acute manic episode
* High psychopathy
* Severe developmental/cognitive disability
* Outstanding legal charges/sentencing

Primary outcomes:
measure: Treatment Retention
measure: The Working Alliance Inventory - Client version (WAI-C)
measure: Canadian Problem Gambling Inventory(CPGI)
measure: State-Trait Anger Expression Inventory-II(STAXI-II)
measure: Addiction Severity Index: Drug and Alcohol Use section
measure: Structured Clinical Interview for the DSM-IV (SCID; APA, 1994), substance use section
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: BC Mental Health and Addiction Services
name: Lorne Korman, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06268327: Adding Adjuvant Cisplatin and Gemicitabine Versus Capecitabine in Triple-negative Breast Cancer Patients in Non pCR After Neoadjuvant Standard Chemotherapy
Official title: Adding Adjuvant Cisplatin and Gemicitabine Versus Capecitabine in Triple-negative Breast Cancer Patients in Non pCR After Neoadjuvant Standard Chemotherapy
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE2
PHASE3
Conditions: Breast Cancer
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2024-02-20
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: In our study; investigator aim To show efficacy and toxicity of Adjuvant cisplatin and gemcitabine in triple-negative breast cancer patients with non pathologically complete response after neoadjuvant chemotherapy To compare outcome of adjuvant cisplatin and gemcitabine versus capecitabine

Detailed description: Patients with operable, primary invasive non inflammatory early TNBC of stage I-IIIB and pathologically verified residual cancer cells (no pathological complete response) after neoadjuvant chemotherapy then underwent adjuvant treatment with gemcitabine plus cisplatin Patients will be followed up every 3 month in first year then every 6 month in the second year then followed up yearly Study will be conducted at Assiut University Hospital with sample size calculation BRACA will be done

Eligibility criteria: Inclusion Criteria:

* Age: 20 years and older.
* Patients with no clinical/radiologic distant metastasis.
* Tumor type: Invasive ductal carcinoma or invaive lobular carcinoma.
* Tumor subtype: triple negative
* patients had operable, primary invasive, noninflammatory early stage I-IIIB TNBC (ER and PR \<1%, HER2 score: 0 or 1)
* Patients with a good performance status (0/1)
* Patients with adequate hematological, cardiac, renal, and hepatic function

Exclusion Criteria:

* Patients who achieve pathologic complete response after neoadjuvant chemotherapy
* inflammatory breast cancer
* Breast cancer patients with distant metastasis
* Patient with hormonal receptor positive /HER2 +ve

Primary outcomes:
measure: Adding adjuvant cisplatin and gemcitabine versus capecitabine in triple-negative Breast cancer patients with non pathologically complete response after neoadjuvant standard chemotherapy
timeFrame: 2 years
Secondary outcomes:
measure: Comparison of patients who receive cisplatin and gemcitabine versus capecitabine in Triple negative breast cancer
timeFrame: 3 years
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06550427: Early Assessment of Lymphoma Treatment Response Using Phased Variant Analysis With Next-Generation Sequencing
Official title: Early Assessment of Aggressive B-Cell Lymphoma Treatment Response and Prediction of Recurrence Using Phased Variant Analysis With Next-Generation Sequencing
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Lymphoma
Hodgkin Lymphoma
T-cell Lymphoma
Waldenstrom Macroglobulinaemia
Keywords: Lymphoma
NGS
Phased Variant
Early Response Assessment
Early Outcome
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
First posted: 2024-08-13
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: pathology proven lymphoma

Brief summary: Lymphoma is a prevalent lymphoid malignancy globally and in Taiwan. Large B-cell lymphoma (LBCL) is the most common subtype of aggressive B-cell lymphoma. LBCL's aggressive nature manifests through extranodal involvement, severe symptoms, and relative refractoriness to therapies, leading to a 5-year overall survival rate of 60-70% across developed countries and poorer outcomes in high-risk patients with primary refractory disease. Chemoimmunotherapy remains the primary treatment for LBCL, requiring comprehensive assessment through clinical and imaging examinations, biomarkers, and molecular testing. Currently, computed tomography (CT) and positron emission tomography (PET) scans are the standard modalities for treatment response evaluation, though their radioactive nature calls for the development of safer alternatives. Circulating tumor DNA (ctDNA) analysis has emerged as a promising field, providing insights into tumor molecular characteristics, clinical status, and treatment response by analyzing DNA fragments released from tumor cells into the bloodstream. Dynamic monitoring of ctDNA during treatment can effectively gauge therapeutic efficacy-decreasing ctDNA concentrations suggest successful treatment, while increasing levels may indicate treatment failure or tumor recurrence. The detection of ctDNA has been much improved through advances in next-generation sequencing (NGS) technologies, particularly taking advantage of analyzing phased variants, consecutive gene mutations on the same chromosome, enhances the sensitivity and specificity.


Eligibility criteria: Inclusion Criteria:

* • Pathology proven lymphoma

  * Age ≥ 18 years old

Exclusion Criteria:

* none

Primary outcomes:
measure: Correlation between ctDNA analyzed by phased variant and early outcome of lymphoma
timeFrame: From the date of enrollment, up to 24 months or date of death from any cause.
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: National Taiwan University Hospital
Study officials:
affiliation: National Taiwan University Hospital
name: Tai-Chung Huang, Ph.D
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03577327: The Gut and Skin Microbiome in Vitiligo Disease Progression
Official title: The Gut and Skin Microbiome in Vitiligo Disease Progression
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Vitiligo
Healthy
Lead sponsor: Northwestern University
Sponsor class: OTHER
First posted: 2018-07-05
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 89
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adults with or without vitiligo who are under the age of 90 years old.

Brief summary: Investigators plan to perform a pilot study that aims to characterize the microbiome of human vitiligo patients with both active and stable disease and compare this to the microbiome of age and sex matched controls. The investigators aim to answer the question whether the gut and skin microbiome of patients with vitiligo differs from the general population.


Eligibility criteria: Inclusion Criteria:

* Patients with and/or without vitiligo lesional expansion over the past year.
* Age/sex-matched controls who do not have a diagnosis of vitiligo
* Subjects who are age 18-89 years of age at time of enrollment
* Subjects who are able and willing to give informed consent for this study and the Dermatology Tissue Acquisition and Biorepository (STU00009443)

Exclusion Criteria:

* Subjects who are younger than 18 years of age or 90 years of age or older
* Subjects who are unable to give consent

Primary outcomes:
measure: Microbiome composition
timeFrame: 12 months
measure: Disease Progression
timeFrame: 12 months
Secondary outcomes:
measure: Diet History Food Frequencies
timeFrame: 12 months
Other outcomes:
Locations:
city: Chicago
country: United States
facility: Northwestern University
state: Illinois
Study officials:
affiliation: Northwestern University
name: I. Caroline Le Poole
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01247727: Heart Rate Variability in Extracorporeal Membrane Oxygenation (ECMO) Patients
Official title: Clinical Application of Multimodal Physiological Signal Analysis in Critical Ill Patients Depending on Extracorporeal Membrane Oxygenation
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Heart Rate Variability
Keywords: Heart rate variability
extracorporeal membrane oxygenation
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
First posted: 2010-11-24
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with the support of extracorporeal membrane oxygenation

Brief summary: National Taiwan University Hospital is the leading center for care of patients with extracorporeal membrane oxygenation (ECMO). The predictable factors associated with outcomes are still lacking in patients with the ECMO support. The aim of this study is to collect the electrical signals stored in the monitor of intensive care units (ICUs), which are analyzed by the bio-informatics software. The pre-, peri-, and post-ECMO heart rate variability, including linear and non-linear analysis is calculated to address the association with outcomes of patients with ECMO. In addition, we collected the demographics, body temperature, respiratory rate, and blood pressure to investigate the causes of heart rate variability.

Detailed description: Inclusion criteria:Adults patients (aged older than 18 years; less than 90 years old) used ECMO for cardiopulmonary support

Exclusion criteria:

1. Patients used illicit drugs
2. Patients received heart transplantation
3. Patients have the history of arrhythmia

Eligibility criteria: Inclusion Criteria:

* Adults patients (aged \> 18 years; less than 90 years old) used ECMO for cardiopulmonary support

Exclusion Criteria:

* Patients used illicit drugs
* Patients received heart transplantation
* Patients have the history of arrhythmia

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: National Taiwan University Hospital
Study officials:
affiliation: National Taiwan University Hospital
name: Wen-Je Ko, M.D., Ph.D.
role: STUDY_CHAIR
References:
Clinical trial NCT00008827: The Use of the Internet to Facilitate Weight Loss and Maintenance.
Official title: The Use of the Internet to Facilitate Weight Loss and Maintenance.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Obesity
Keywords: Obesity
Behavioral weight control
Internet
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Sponsor class: NIH
First posted: 2001-01-17
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Primary purpose: TREATMENT

Brief summary: This project is assessing the effectiveness of using the Internet as a tool to facilitate the maintenance of weight lost in a behavioral weight control program. Participants attend a standard behavioral weight control intervention via Interactive Television and after 6 months are randomly assigned to one of three groups; a control group, an in-person weight maintenance group and a maintenance group that meets over the Internet. This research project is being conducted in Vermont.


Eligibility criteria: Inclusion Criteria:

* BMI between 25 and 39.9
* Internet connection

Exclusion Criteria:

* Major medical problems
* Inability to walk for exercise

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Burlington
country: United States
facility: University of Vermont
state: Vermont
Study officials:
affiliation: University of Vermont
name: Jean Harvey-Berino
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02387827: Comparing of Long Bout and Short Bouts of Similar Volume of Walking in Obese on Weight Loss During a Weight Loss Program
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Obesity
Overweight
Keywords: long bout physical activity
short bout physical activity
Caloric Restriction
Lead sponsor: Novindiet Clinic
Sponsor class: OTHER
Collaborators: name: University of Nottingham
name: Tehran University of Medical Sciences
First posted: 2015-03-13
Enrollment: 60
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this present study is to determine if a daily walking program of 50 continuous minutes (long bout) or two 25-minute bouts (short bouts) in similar volume on body weight, abdominal fat mass deposition and cardiometabolic measures in overweight and obese women receiving a low calorie diet for 24 weeks.


Eligibility criteria: Inclusion Criteria:

* Must have Body mass index (BMI) between 27-35 kg/ m².
* were sedentary (reported exercising \<20 min/d for the previous 6 month) and healthy
* Must be able to have moderate exercise.
* Must be interested to have weight loss.

Exclusion Criteria:

* Participating in a research project involving weight loss or physical activity in the previous six months.
* Pregnancy or lactation during the previous 6 months, or planned pregnancy in the next six months.
* Taking medication that could affect metabolism or change body weight.
* Report heart problems, chest pain, and cancer within the last five years.
* Smoking
* Menopause
* Diagnosis of any chronic disease such as fatty liver, cancer, chemo/radio therapy, heart disease, immune compromised conditions, abnormal thyroid hormone level.

Primary outcomes:
measure: weight loss
timeFrame: 24 weeks
measure: Body mass index reduction
timeFrame: 24 weeks
Secondary outcomes:
measure: waist circumference
timeFrame: 24 weeks
measure: Fasting plasma glucose level
timeFrame: 24 weeks
measure: lipid profiles
timeFrame: 24 weeks
measure: Insulin resistance (HOMA)
timeFrame: 24 weeks
Other outcomes:
Locations:
city: Tehran
country: Iran, Islamic Republic of
facility: NovinDiet Clinic
Study officials:
References:
citation: Madjd A, Taylor MA, Delavari A, Malekzadeh R, Macdonald IA, Farshchi HR. Effect of a Long Bout Versus Short Bouts of Walking on Weight Loss During a Weight-Loss Diet: A Randomized Trial. Obesity (Silver Spring). 2019 Apr;27(4):551-558. doi: 10.1002/oby.22416. Epub 2019 Feb 9.
Clinical trial NCT04493827: Distribution and Prognostic Impact of Oncogenic Drivers in Metastatic Lung Adenocarcinoma : a Retrospective Monocentric Study in Nancy University Hospital Center
Official title: Distribution and Prognostic Impact of Oncogenic Drivers in Metastatic Lung Adenocarcinoma : a Retrospective Monocentric Study in Nancy University Hospital Center
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Adenocarcinoma of Lung Stage IV
Adenocarcinoma of Lung, Response to Tyrosine Kinase Inhibitor in, Somatic
Lead sponsor: Central Hospital, Nancy, France
Sponsor class: OTHER
First posted: 2020-07-30
Enrollment: 114
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with metastatic lung adenocarcinoma diagnosed between 2012 and 2014 with a medical follow-up entirely done in Nancy Central Hospital

Brief summary: The recent discovery of oncogenic drivers has revolutionized the management of advanced lung cancer by development of tyrosine kinase inhibitors targeted therapies. Prevalence of daily tobacco use is evaluated at 31,3 % in Grand-Est region, the only French region with a statistically significative difference for smoking habits. This region shows a higher incidence (+ 13 %) and mortality for lung cancer in comparison to the average for other French regions. The objectives of our studie were to estimate the distribution of oncogenic drivers and analyse their prognostic impacts in the Nancy University Hospital Center metastatic lung adenocarcinoma's population.


Eligibility criteria: Inclusion Criteria:

* Lung adenocarcinoma
* Patients diagnosed at a metastatic stage
* Patient who benefited an oncogenic driver research on their histologic samples
* Medical follow-up entirely done in Nancy Central Hospital

Exclusion Criteria:

* Patients with double histology
* Synchronous cancer
* Patients with surgical care

Primary outcomes:
measure: Overall survival
timeFrame: over a period of 5 years (Day 0 = anatomopathological diagnosis)
measure: Progression Free survival
timeFrame: over a period of 5 years (Day 0 = anatomopathological diagnosis)
measure: Distribution in percentage of main oncogenic drivers in histological samples from metastatic lung adenocarcinoma
timeFrame: At base line (Day 0 = anatomopathological diagnosis)
Secondary outcomes:
measure: Distribution in percentage of metastasis sites according oncogenic drivers
timeFrame: At baseline (Day 0 = anatomopathological diagnosis)
Other outcomes:
Locations:
city: Vandœuvre-lès-Nancy
country: France
facility: Centre Hospitalier Régional Universitaire
state: Meurthe Et Moselle
Study officials:
affiliation: Nancy Central Hospital
name: Angelica Tiotiu
role: STUDY_DIRECTOR
References: